Difficulty Urinating
Rodney L. Wright
Dr. Wright’s clinical interests include HIV during pregnancy, infectious diseases, sexually transmitted infections, global women’s health and maternal fetal medicine.
Following his clinical interests, Dr. Wright’s research focuses on HIV during pregnancy, prevention of perinatal HIV transmission, cervical dysplasia, HPV and global women’s health.
<p>Rodney L. Wright, MD, MSc, is Director, Obstetrics and Gynecology, Wakefield Campus at Montefiore and Professor of Obstetrics and Gynecology and Women’s Health, Division of Maternal Fetal Medicine at our Albert Einstein College of Medicine. Dr. Wright’s clinical interests include HIV during pregnancy, infectious diseases, sexually transmitted infections, global women’s health and maternal fetal medicine.</p><p>After receiving his Bachelor of Arts in biology and psychology from Emory University, Dr. Wright went on to the University of Pennsylvania School of Medicine, earning his Doctor of Medicine. His post graduate training began at the University of California, Irvine, where he completed a four-year residency in obstetrics and gynecology. Several years later, Dr. Wright pursued a three-year fellowship in maternal fetal medicine at Montefiore-Einstein. After completing this, he continued his education at Einstein, earning his Master of Science in clinical research methods.</p><p>Following his clinical interests, Dr. Wright’s research focuses on HIV during pregnancy, prevention of perinatal HIV transmission, cervical dysplasia, HPV and global women’s health. He’s shared his research and expertise through many peer-reviewed journals, abstracts and invited presentations. He currently serves on the US Department of Health and Human Services Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission.</p><p>An active member within the community, Dr. Wright is a member of the New York State AIDS Advisory Council and the New York State Taskforce on Maternal Mortality. He was awarded the Bronx County Medical Society “Peer to Peer” Excellence in Medicine Award. Dr. Wright received the New York State Commissioner of Health Commissioner’s Special Recognition Award in recognition of his work as co-chair of the New York State Perinatal HIV Guidelines Committee and service to the New York State Ending the Epidemic (AIDS) Task Force. Dr. Wright is board certified in both Maternal Fetal Medicine and Obstetrics and Gynecology and is a member of several professional organizations including the New York Obstetrical Society, the Society for Maternal-Fetal Medicine and the American College of Obstetricians and Gynecologists.</p>
Danny Woo
Kara L. Watts
Clinical practice focuses on BPH, endourology, and prostate cancer detection and ablation.<quillbot-extension-portal></quillbot-extension-portal>
Work on quality improvement in healthcare and active surveillance and focal ablation in prostate cancer.<quillbot-extension-portal></quillbot-extension-portal>
<p>Dr. Kara L. Watts, Associate Professor of Urology, joined the urology faculty at Montefiore in 2016. She completed a fellowship in Quality and Performance Improvement in Healthcare and an extended observership in focal ablation for prostate cancer in the UK. She serves as the Director of Quality Assurance and Improvement for the Department of Urology and leads the prostate cancer screening program.</p><p>Dr. Watts' clinical practice focuses on BPH, endourology, and prostate cancer detection and ablation. She also offers image-guided focal ablation for localized prostate cancer. She has a particular interest in active surveillance of prostate cancer and incorporating imaging modalities, particularly MRI imaging, into the diagnosis and treatment of localized prostate cancer.</p><p>Dr. Watts has numerous peer-reviewed publications, written several book chapters and co-edited a textbook. She has presented both nationally and internationally at various conferences and with the AUA regarding her work on quality improvement in healthcare and active surveillance and focal ablation in prostate cancer. She is involved in several national and international committees and editorial boards, including the AUA Quality Improvement and Patient Safety Committee, the Prostate Cancer Active Surveillance Research Initiative Advisory Committee, and the Urology Times Editorial Board.</p>
Dawn M. Wahezi
<p>Dr. Wahezi attended medical school at the University of Buffalo, School of Medicine and Biomedical Sciences. She completed her residency training in Pediatrics at The Children’s Hospital at Montefiore, where she stayed on as the inaugural fellow in Pediatric Rheumatology. She subsequently joined the faculty in the Department of Pediatrics at Montefiore and completed a Master’s Degree in clinical research through the Einstein-Montefiore Institute for Clinical and Translational Research Program. Dr. Wahezi is currently an Assistant Professor of Pediatrics at the Albert Einstein College of Medicine and serves as the Program Director of the Pediatric Rheumatology Fellowship Program. </p>
<p>Dr. Wahezi has a special interest in juvenile dermatomyositis (JDM) and was awarded the Cure JM Foundation Early Investigator Award for her research in premature atherosclerosis. She has additionally established a pediatric Systemic Lupus Erythematosus (SLE) Cohort and participates in a dedicated, multi-disciplinary pediatric Lupus Nephritis Clinic. Dr. Wahezi is currently engaged in several research projects within the domains of JDM and SLE, contributing to over 40 peer reviewed manuscripts, reviews and scientific abstracts.</p>
<p>Dr. Wahezi is an active member of both the JDM subcommittee and SLE subcommittee within the Childhood Arthritis and Rheumatology Research Alliance (CARRA) and has participated in numerous observational and comparative effectiveness research protocols through this research consortium. </p>
<span style="color:#4d4d4d;font-family:Arial, Helvetica, source-code-pro, Menlo, Monaco, Consolas, 'Courier New', monospace;font-size:16px;background-color:#ffffff;">Pediatric Rheumatology</span>
Dr. Wahezi has a particular research interest in juvenile dermatomyositis (JDM) and was awarded the Cure JM Foundation Early Investigator Award for her research in premature atherosclerosis.
<p></p>Dawn Wahezi, MD, MS, is Chief of the Division of Pediatric Rheumatology and Director of the Pediatric Rheumatology Fellowship Program at the Children’s Hospital at Montefiore. She is also Associate Professor of Pediatrics at our Albert Einstein College of Medicine.<br /><br />Dr. Wahezi received her Bachelor of Science from Loyola College and earned her Doctor of Medicine at the State University of New York at Buffalo, Jacobs School of Medicine and Biomedical Sciences. She obtained a Master of Science in Clinical Research at Albert Einstein College of Medicine, and did her residency and fellowship training at CHAM.<br /><br />Dr. Wahezi’s clinical and research interests include juvenile dermatomyositis (JDM) and juvenile systemic lupus erythematosus (SLE). At CHAM, she established an interdisciplinary clinic and comprehensive patient registry for children with JDM and SLE.. Dr. Wahezi is an active member of the American Academy of Pediatrics Rheumatology Advisory Board and the Childhood Arthritis and Rheumatology Research Alliance (CARRA).<p></p>
Kristine E. Torres-Lockhart
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">Kristine Torres-Lockhart, MD, FASAM is an Assistant Professor of Medicine in the Division of General Internal Medicine and Department of Psychiatry and Behavioral Sciences at Montefiore Medical Center and the Albert Einstein College of Medicine, as well as the founding director of the Addiction Consult Service at Montefiore's Weiler Hospital. She is Program Director of the Addiction Medicine Fellowship and Co-Director of the Addiction Medicine rotation for medical trainees. An addiction medicine and internal medicine physician, she leads the development and implementation of health system interventions to improve substance use disorder (SUD) care in acute care settings and transitions of care to post-acute and ambulatory care settings.</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><br />Dr. Torres-Lockhart provides SUD treatment, HIV/AIDS care, hepatitis C treatment, and general internal medicine care at several sites across Montefiore Medical Center, including a community health care center. She also actively teaches and supervises medical students, residents, and fellows. She is double board certified in addiction medicine and internal medicine and credentialed as an HIV specialist by the American Academy of HIV Medicine. <br /><br />Dr. Torres-Lockhart completed her fellowship training in addiction medicine at Montefiore Medical Center. Prior to arriving at Montefiore, she completed her residency training in internal medicine and primary care at Brigham and Women’s Hospital in Boston, MA, where she also served as primary care chief medicine resident at the West Roxbury and Jamaica Plain Veterans Affairs Medical Centers. She received her undergraduate degree from Dartmouth College and her medical degree from the Geisel School of Medicine at Dartmouth. She is the PI for a HRSA training grant and co-PI for an OASAS training grant to lead the development of educational opportunities in building the addiction medicine workforce. She currently serves on the Board of Directors for the New York Society of Addiction Medicine previously as Communication Chair and now as Secretary. </p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">Singh-Tan, S., <strong>Torres-Lockhart, K.</strong>, Jakubowski, A., Lu, T., Starrels, J., De Lima, P., Arnsten, J., Nahvi, S., Southern, W. (2023). Addiction Consult Service and Inpatient Outcomes Among Patients with Alcohol Use Disorder. /J Gen Intern Med/, 1-8. doi:10.1007/s11606-023-08202-7</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"> </p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">Jakukowski, A., Singh-Tan, S., <strong>Torres-Lockhart, K</strong>., Nahvi, S., Stein, M., Fox, A. D., & Lu, T. (2023). Hospital-based clinicians lack knowledge and comfort in initiating medications for opioid use disorder: opportunities for training innovation. /Addict Sci Clin Pract, 18/(1), 31. doi:10.1186/s13722-023-00386-x</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"> </p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">Calcaterra, S. L., Bottner, R., Martin, M., Englander, H., Weinstein, Z. M., Weimer, M. B., Lambert, E., Ronan, M., Huerta, S., Zaman, T., Ullal, M., Peterkin, A., <strong>Torres-Lockhart, K.</strong>, Buresh, M., O’Brien, M., Synder, H., Herzig, S. J. (2022). Management of opioid use disorder, opioid withdrawal, and opioid overdose prevention in hospitalized adults: A systematic review of existing guidelines. /J Hosp Med, 17(9),/679-692/./doi:10.1002/jhm.12908</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"> </p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><strong>Torres-Lockhart, K.</strong> E., Lu, T. Y., Weimer, M. B., Stein, M. R., & Cunningham, C. O. (2022). Clinical Management of Opioid Withdrawal. /Addiction, 117/(9), 2540-2550. doi:10.1111/add.15818</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"> </p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">Cunningham, C. O., Khalid, L., Deng, Y., <strong>Torres-Lockhart, K.</strong>, Masyukova, M., Thomas, S., Zhang, C., Lu, T. (2022). A comparison of office-based buprenorphine treatment outcomes in Bronx community clinics before versus during the COVID-19 pandemic. /J Subst Abuse Treat, 135/, 108641. doi:10.1016/j.jsat.2021.108641</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"> </p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">Joseph, G., <strong>Torres-Lockhart, K.</strong>, Stein, M. R., Mund, P. A., & Nahvi, S. (2021). Reimagining patient-centered care in opioid treatment programs: Lessons from the Bronx during COVID-19. /J Subst Abuse Treat, 122/, 108219. doi:10.1016/j.jsat.2020.108219</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"> </p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">He, L., <strong>Torres-Lockhart, K.</strong>, Forster, N., Ramakrishnan, S., Greninger, P., Garnett, M. J., McDermott, U., Rothenberg, S.M., Benes, C.H., Ellisen, L. W. (2013). Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma. /Cancer Discov, 3/(3), 324-337. doi:10.1158/2159-8290.CD-12-0417</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"> </p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">Ibrahim, Y. H., Garcia-Garcia, C., Serra, V., He, L., <strong>Torres-Lockhart, K</strong>., Prat, A., Anton, P., Cozar, P., Guzman, M., Grueso, J., Rodriguez, O., Calvo, M.T., Aura, C., Diez, O., Rubio, I.T., Perez, J., Rodon, J., Cortes, J., Ellisen, L.W., Scaltriti, M., Baselga, J. (2012). PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. /Cancer Discov, 2/(11), 1036-1047. doi:10.1158/2159-8290.CD-11-0348</p>
<p>Kristine E. Torres-Lockhart, MD, FASAM, is Director, Addiction Medicine Fellowship Program at Montefiore Einstein, Founding Director, Addiction Consult Service at Weiler Hospital and Assistant Professor, General Internal Medicine and Psychiatry and Behavioral Sciences at our Albert Einstein College of Medicine. Dr. Torres-Lockhart is a general internist, primary care provider and addiction medicine specialist. She focuses on caring for people who use substances and people with substance use disorders, providing care in hospital settings and in outpatient clinics.</p><p>After obtaining her Bachelor of Arts in neuroscience from Dartmouth College in 2010, Dr. Torres-Lockhart earned her Doctor of Medicine at the Geisel School of Medicine at Dartmouth in 2016. She completed an internship and residency in internal medicine and primary care at Brigham and Women’s Hospital in 2019. Following this, Dr. Torres-Lockhart completed a fellowship in addiction medicine at Montefiore Einstein in 2020.</p><p>Dr. Torres-Lockhart's research focuses on evidence-based and harm-reduction-oriented strategies for addressing substance use disorder care in acute care settings, integration of addiction medicine into medical education and optimizing transitions of care for people who use drugs. She has been principal investigator and co-investigator on funded research projects and her work has been published in numerous peer-reviewed publications. Dr. Torres-Lockhart has also shared her work through numerous invited presentations, abstracts and poster presentations. She is a reviewer for scientific journals, including Addiction Science and Clinical Practice, the Journal of Addiction Medicine, the Journal of Substance Abuse Treatment and the Journal of Hospital Medicine.</p><p>Dr. Torres-Lockhart is board certified by the American Board of Internal Medicine and the American Board of Preventive Medicine with certification in Addiction Medicine. She is a Fellow of the American Society of Addiction Medicine, board member of the New York Society of Addiction Medicine and member of the Association for Multidisciplinary Education and Research in Substance Use and Addiction. In 2022, Dr. Torres-Lockhart received the President’s Award at the New York Society of Addiction Medicine’s Annual Conference. In 2023, she received the Quality Improvement Champion honor at the United Hospital Fund's Tribute to Excellence in Health Care and was a Rising Star Nominee for the Department of Medicine’s Physician Recognition Awards at Montefiore Einstein.</p>
Peter L. Tenore
Dr. Tenore is a Medical Director in the Division of Substance Abuse and is a wekk known figure in this field, having published in several journals and providing education in substance abuse to local and state agencies. He is an advisor to the New York State Ofice of Alcoholism and Substance Abuse Services and the federal Center for Substance Abuse Treatment. He is certified in Internal Medicine and by examination in Addiction Medicine and a New York State HIV Provider. His particular interests are management of cocaine and other addictions as well as providing hepatitis C and HIV treatment in the methadone clinic setting.
DINO-VAMP: A Helpful Acronym in Determining Optimal Methadone Dosing and Brief review of Dosing Literature, Journal of Maintenance in the Addictions, Vol.2(4).
Guidance On Optimal Methadone Dosing, Addiction Treatment Forum, Vol.12 (2).
Methadone:A Medical Model in "Innovations in Substance Abuse Treatment and Policy," Yale University Center for Interdisciplinary Research, Yale Publicatinos, New Haven, CT.
Three Oral Formulations of Methadone: A Clinical and Pharmacodynamic Comparison, Journal of Substance Abuse Treatment, Vol. 17(3), Gourevitch, Hartell, Tenore, et al.
Nhan Tai
Martina Stehlikova
<p>In-patient internal medicine with a special interest in hematology. Anemia, thrombocytopenia and coagulopathy in hospitalised patients.</p>